Autoimmune Clinical Manifestations following Intravesical Bacillus Calmette-Guérin and Interferon alpha 2b Immunotherapy for Superficial Bladder Cancer

Publisher： Karger

E-ISSN： 1661-7657|3|1|36-40

ISSN： 1661-7649

Source： Current Urology, Vol.3, Iss.1, 2009-05, pp. : 36-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 80, Iss. 1, 2008-01 ,pp. : 74-79

Karger

Access to resources Recommend Favorite

Importance of Urinary Interleukin-18 in Intravesical Immunotherapy with Bacillus Calmette-Guérin for Superficial Bladder Tumors

By  

Urologia Internationalis, Vol. 75, Iss. 2, 2008-07 ,pp. : 114-118

Karger

Access to resources Recommend Favorite

Urinary Fibronectin Levels in Patients Treated with Intravesical Bacillus Calmette-Guérin for Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 4, 2006-01 ,pp. : 198-201

Karger

Access to resources Recommend Favorite

Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in High-Risk Superficial Bladder Cancer: A Randomised Prospective Study

By  

Urologia Internationalis, Vol. 84, Iss. 1, 2010-02 ,pp. : 23-27

Karger

Access to resources Recommend Favorite

Cytological Changes Induced by Intravesical Bacillus Calmette-Guérin Therapy for Superficial Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 74-81

Karger

Access to resources Recommend Favorite